On July 15, 2019 Meningioma Mommas was proud to award the University of Colorado $29,430 to fully fund this research. The grant was made in honor of Dr Randa Alsabeh and Nickie Gosselin.
Meningioma Mommas is a 501(c)(3) not-for-profit organization, which provides support and valuable resources to all those affected by meninigoma brain tumors. We are committed to raising critical funding for meningioma specific research. While meningiomas are the most common primary brain tumor, they don’t warrant the funding they deserve because of their mistakenly “benign” label.
However, depending on where the tumor is located, they can cause devastating deficits such as blindness, paralysis, epilepsy, deafness and cognitive impairment, to name but a few. They can and do kill. Meningioma Mommas is committed to ONLY FUNDING MENINGIOMA SPECIFIC RESEARCH. To date we have donated $366,593 for that purpose and are now asking for help to fund a new project by a team of researchers at the University of Colorado whom we have previously funded.
"Meningiomas are a common brain tumor, considered to be the most prevalent primary brain tumor in the central nervous system. In spite of their burden, no FDA approved pharmacotherapies exist for the treatment of these tumors. Through our work with Meningioma Mommas, we have created a high throughput drug screen that allows us to directly measure the sensitivity of individual tumors to hundreds of FDA approved compounds. This approach has identified several possible treatments that have the ability to treat meningiomas broadly by targeting epigenetic processes. Many of the drugs in this class can cross the blood brain barrier making these ideal candidates for further studies. This proposal aims to perform the studies required for clinical trial consideration. If successful, we will take advantage our multi-institutional clinical trial mechanism to immediately open trials across North America, providing hope and treatment options for patients with meningiomas."
"Our collaborative group is dedicated to identifying the most effective therapies for the treatment of brain tumors. Meningiomas, in particular, are a neglected family of tumors that have few treatment options in spite of being one of the most prevalent CNS tumors. Our team of clinicians and scientists witness the devastation these tumors can have on patients and their families, and we recognize the need to address the paucity of treatment options. We have deliberately assembled a team comprised of neuro-oncologists, neurosurgeons, and scientists at two different institutions to find new cures for these tumors. Collectively, we can make greater strides than any of our individual efforts. Our mission is to provide hope for those suffering from meningiomas, and to find better treatments so we can effectively care for these patients."